Effect of Liver Dysfunction on S-1 Therapy Induced Adverse Effects: A Retrospective Cohort Study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated total bilirubin (T-Bil) levels in patients receiving S-1 chemotherapy correlate with decreased platelet counts. This suggests S-1 administration may cause thrombocytopenia in patients with liver dysfunction.
Area Of Science
- Oncology
- Pharmacology
- Hepatology
Background
- Renal dysfunction often requires S-1 dose reduction.
- Decreased dihydropyrimidine dehydrogenase (DPD) activity can cause adverse events with 5-FU.
- Current guidelines use total bilirubin (T-Bil) ≤1.5x ULN for S-1 safety, but the link to liver dysfunction and dose reduction is unclear.
Purpose Of The Study
- To investigate the relationship between liver dysfunction, indicated by T-Bil levels, and S-1 dose reduction.
- To determine the clinical outcomes associated with varying T-Bil levels in patients undergoing S-1 monotherapy.
Main Methods
- Retrospective analysis of 883 patients receiving S-1 monotherapy.
- Patients categorized into Low T-Bil (≤2.25) and High T-Bil (>2.25) groups.
- Primary outcome: variation in blood sampling results; analyzed clinical outcomes including RBC and PLT counts.
Main Results
- 883 patients and 7,511 treatment instances analyzed; 7,245 in Low T-Bil, 266 in High T-Bil group.
- Significant correlations found between T-Bil group and RBC count, PLT count, and T-Bil level.
- High T-Bil group showed significant decreases in RBC and PLT counts compared to the Low T-Bil group.
Conclusions
- S-1 administration in patients with liver dysfunction and elevated T-Bil may lead to thrombocytopenia.
- Monitoring T-Bil levels is crucial for managing S-1 therapy in patients with liver impairment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...